AI Telephone

Emily Chen is a 28-year-old female with a confirmed diagnosis of mild intermittent asthma, with onset in childhood. She has no known drug allergies.

Her current medication regimen for asthma management includes two active prescriptions: albuterol 90 mcg/actuation metered dose inhaler, 2 puffs as needed for shortness of breath (typically used 2–3 times per week), and montelukast 10 mg oral tablet taken once daily for maintenance therapy.

Pulmonary function testing has been completed with final results available. Her FEV1 measured at 92% of predicted, which was interpreted as within normal limits.

Emily Chen is a female born in 1997. Her allergy record is active and confirmed, documenting no known drug allergies.

She has an active, confirmed problem-list diagnosis of asthma, described as mild intermittent in severity, with onset since childhood.

For symptom relief, she has an active medication order for albuterol 90 mcg/actuation metered-dose inhaler: inhale 2 puffs by inhalation as needed for shortness of breath/dyspnea, typically 2–3 times per week (dose: 2 puffs per use). For asthma maintenance, she also has an active medication order for montelukast 10 mg oral tablet: take 10 mg by mouth once daily.

A pulmonary function test observation (final) documents FEV1 % predicted = 92%. No appointments or scheduling details are included in the provided records.

Emily Chen is a 28-year-old female with a confirmed diagnosis of mild intermittent asthma, which has been active since the age of 5. Her current medication regimen includes albuterol 90mcg inhaler, to be used as 2 puffs via inhalation as needed for shortness of breath, and montelukast 10mg oral tablet, taken daily. A recent pulmonary function test conducted on February 15, 2024, showed normal results, with an FEV1/FVC ratio of 92%. Emily has no known drug allergies.

Emily Chen is a 28-year-old female (born 1996) with no known drug allergies. She has an active diagnosis of mild intermittent asthma. A recent exam recorded her FEV1/FEV1 predicted at 92%. To manage her condition, she is currently prescribed an Albuterol 0.09 mg/actuation inhaler, with instructions to take 2 puffs as needed for shortness of breath (typically 2-3 times per week), as well as Montelukast 10 mg oral tablets to be taken as 10mg daily.

Emily Chen, a 28-year-old female, has a confirmed diagnosis of mild intermittent asthma since childhood, which is currently active. Her pulmonary function tests show a FEV1 of 92% predicted, indicating well-controlled asthma. She has no known drug allergies. For her asthma management, Emily has been prescribed two medications. The first is an albuterol 90mcg inhaler, to be used as needed at a dose of 2 puffs for shortness of breath, typically required 2-3 times per week. The second medication is montelukast 10mg, which she takes daily as a maintenance therapy. These medications are both currently active prescriptions.

Emily Chen is a female patient born in 1997 who has no known drug allergies. She has an active, confirmed diagnosis of mild intermittent asthma, which she has had since childhood. A recent observation shows her FEV1 is at 92% of predicted value. To manage her condition, she has two active medication orders: montelukast 10 mg taken orally once daily for asthma maintenance, and an albuterol 90 mcg inhaler with instructions to inhale 2 puffs as needed for shortness of breath (typically used 2 to 3 times per week).

Emily Chen is a female patient born in 1997. She has a confirmed, active diagnosis of mild intermittent asthma (uncomplicated) (SNOMED CT 427679007; ICD-10-CM J45.20), listed as a problem-list item with onset in childhood. Her allergy record indicates no known drug allergies, documented as active and confirmed (“No known drug allergies”).

For asthma management, she has two active medication orders. She is prescribed albuterol 0.09 mg/actuation metered dose inhaler (albuterol 90 mcg inhaler) with instructions to take 2 puffs as needed for shortness of breath, typically 2–3 times per week; the dose is 2 puffs per use and the administration is documented as inhalation (route text “Inhalation” is present, though the coded route is “Oral route”). She is also prescribed montelukast 10 mg oral tablet for maintenance with directions 10 mg by mouth once daily.

Pulmonary function testing was completed with a final report categorized under pulmonary function (“Pulmonary Function Test” / “Measurement of respiratory function”). The conclusion states FEV1 92% predicted, interpreted as within normal limits. A corresponding final observation documents FEV1 measured/predicted = 92%, with interpretation Normal / within normal limits. No appointments or scheduling details are included in the provided records.

Emily Chen is a 29-year-old female with no known drug allergies. She has a confirmed diagnosis of mild intermittent asthma, with onset at age 5. Her most recent pulmonary function test, performed on January 15, 2023, showed an FEV1/FVC ratio of 92%, which was interpreted as normal.

Her current active medications include albuterol 90 mcg inhaler, 2 puffs as needed for shortness of breath via inhalation (maximum 2 puffs per day), and montelukast 10 mg taken orally once daily.